Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE

COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13D/A
(Amendment No. 1)

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

(Name of Issuer)

 

(Title of Class of Securities)

 

(CUSIP Number)

 

Eugene Siklos, President

c/o Thomvest Asset Management Ltd.

65 Queen Street West, Suite 2400

Toronto, Ontario, M5H 2M8

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

 

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act.

 

 

 

CUSIP No. 53272L103

 

1	NAMES OF REPORTING PERSONS
	Structured Alpha LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	o
				(b)	o
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				o
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			23,992,231(1)
		8	SHARED VOTING POWER
			0
		9	SOLE DISPOSITIVE POWER
			23,992,231(1)
		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	23,992,231(1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	71.6%(2)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	PN

 

(1) Includes 4,116,102 common shares, no par value per share (the Common Shares), of Liminal Biosciences Inc. (the Issuer) issuable to Structured Alpha LP (SALP) upon the exercise of Warrants (as defined in Item 3 of the original Schedule 13D).

 

(2) This percentage is calculated based upon 29,385,945 outstanding Common Shares of the Issuer as of November 9, 2020 as reported in the Issuers Form 6-K filed with the Securities and Exchange Commission (the SEC) on November 12, 2020, plus an additional 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

2

 

CUSIP No. 53272L103

 

1	NAMES OF REPORTING PERSONS
	Thomvest Asset Management Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	o
				(b)	o
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				o
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Ontario, Canada
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			23,992,231(1)
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			23,992,231(1)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	23,992,231(1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	71.6%(2)
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	CO

 

(1) Includes 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

(2) This percentage is calculated based upon 29,385,945 outstanding Common Shares of the Issuer as of November 9, 2020 as reported in the Issuers Form 6-K filed with the SEC on November 12, 2020, plus an additional 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

3

 

CUSIP No. 53272L103

 

 

(1) Mr. Thomson disclaims beneficial ownership of the Common Shares as described in Item 5.

 

(2) Includes 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

(3) This percentage is calculated based upon 29,385,945 outstanding Common Shares of the Issuer as of November 9, 2020 as reported in the Issuers Form 6-K filed with the SEC on November 12, 2020, plus an additional 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants

 

4

 

CUSIP No. 53272L103

 

 

(1) Mr. Siklos disclaims beneficial ownership of the Common Shares as described in Item 5.

 

(2) Includes 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

(3) This percentage is calculated based upon 29,385,945 outstanding Common Shares of the Issuer as of November 9, 2020 as reported in the Issuers Form 6-K filed with the SEC on November 12, 2020, plus an additional 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants

 

5

 

Explanatory Note

 

This Amendment No. 1 (this Amendment No. 1) to the original Schedule 13D previously filed on November 9, 2020 is being filed by Structured Alpha LP (SALP), Thomvest Asset Management Ltd. (Thomvest), Mr. Peter J. Thomson and Mr. Eugene Siklos (collectively, the Reporting Persons) to reflect the receipt by SALP of an additional 789,473 warrants to purchase up to 789,473 common shares, no par value per share (the Common Shares), of Liminal Biosciences Inc. (the Issuer).

 

Information and defined terms reported in the original Schedule 13D remain in effect except to the extent that it is amended or superseded by information or defined terms contained in this Amendment No. 1.

 

Item 3. Source and Amount of Funds or Other Consideration.

 

Item 3 of the original Schedule 13D is hereby amended and supplemented as follows:

 

On November 25, 2020, the Issuer, SALP and Armistice Capital Master Fund Ltd. agreed to amend the Securities Purchase Agreement, following which SALP received an additional 789,473 2020 Warrants to purchase up to 789,473 Common Shares on the same terms as the original Securities Purchase Agreement.

 

Item 4. Purpose of Transaction.

 

The information set forth in Item 3 of this Amendment No. 1 is hereby incorporated by reference into Item 4 of the original Schedule 13D.

 

Item 5. Interest in Securities of the Issuer.

 

Item 5(a)-(c) of the original Schedule 13D is hereby amended and restated as follows:

 

(a)-(b) The aggregate number and percentage of Common Shares held by the Reporting Persons to which this Schedule 13D relates is 23,992,231 shares, constituting approximately 71.6% of the Issuers currently outstanding Common Shares. This percentage is calculated based upon 29,385,945 outstanding Common Shares of the Issuer as of November 9, 2020 as reported in the Issuers Form 6-K filed with the SEC on November 12, 2020, plus an additional 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

(i) SALP

 

 

(1) Includes 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

(ii) Thomvest

 

 

(1) Includes 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

(iii) Mr. Thomson

 

 

6

 

 

(1) Includes 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

(iv) Mr. Siklos

 

	(a)	Mr. Siklos may be deemed the beneficial owner of 23,992,231(1) Common Shares, constituting a percentage of approximately 71.6%.
	(b)	Sole voting power to vote or direct vote: 0 Common Shares Shared voting power to vote or direct vote: 23,992,231(1) Common Shares Sole power to dispose or direct the disposition: 0 Common Shares Shared power to dispose or direct the disposition: 23,992,231(1) Common Shares

 

(1) Includes 4,116,102 Common Shares issuable to SALP upon the exercise of the Warrants.

 

(c) Other than the transactions described herein and in the original Schedule 13D, there have been no transactions by the Reporting Persons in the Common Shares during the past 60 days.

 

Neither the filing of this Schedule 13D nor any of its contents shall be deemed an admission that either of Mr. Thomson or Mr. Siklos is the beneficial owner of the Common Shares or Warrants referred to herein for purposes of Section 13(d) or Section 13(g) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

The information set forth in Item 3 of this Amendment No. 1 is hereby incorporated by reference into Item 6 of the original Schedule 13D. In addition, the Reporting Persons expect the Common Shares issuable upon exercise of the additional 2020 Warrants referred to in this Amendment No. 1 will be registered for resale in the registration statement contemplated by the Registration Rights Agreement.

 

Item 7. Materials to Be Filed as Exhibits.

 

Item 7 of the original Schedule 13D is hereby amended and supplemented as follows:

 

Exhibit 99.6 Amendment No. 1, dated November 25, 2020, to the Securities Purchase Agreement

 

7

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

 

8